SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses 10% Stake in Ionis Pharmaceuticals
Beneficial Ownership Report
T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 10.0% of Ionis Pharmaceuticals Inc.'s common stock.
Summary
- T. Rowe Price Investment Management, Inc. has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Ionis Pharmaceuticals Inc.
- The filing indicates that T. Rowe Price Investment Management, Inc. beneficially owns an aggregate of 15,851,863 shares of Ionis Pharmaceuticals Inc. common stock.
- This ownership represents 10.0% of the total class of securities.
- T. Rowe Price Investment Management, Inc. holds sole voting power over 15,815,345 shares and sole dispositive power over 15,851,863 shares.
- The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: This document is a factual disclosure of beneficial ownership and does not contain information that would typically convey positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA This document is a beneficial ownership report and does not contain forward-looking statements or guidance from the issuer.
Industry Context
This filing is a standard disclosure required by the SEC when an institutional investor acquires beneficial ownership of more than 5% of a company's voting class of securities. It provides transparency regarding significant ownership stakes in publicly traded companies, which can be of interest to other investors tracking institutional positions.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, potentially influencing market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of event which required the filing of this statement (ownership threshold met or changed) |
| 02/07/2025 | Date the Schedule 13G Amendment No. 2 was signed |
Keywords
Ionis Pharmaceuticals, T. Rowe Price Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.